Sterility assay, line item 119 units: each catalog#: 510120GMP.BSV

Ended Awarded Last action

Contract number
HHSN26100029
Awardee
Awarding agency
Obligated
$36,008

Award facts

Contract value 100% obligated
$36,008.23 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Competed under SAP · 3 offers Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Rockville, MD 20850, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Change Order 1 $0
Original award $36,008

About this award

This federal contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute to Bioreliance Corporation, a foreign-owned for-profit organization. The contract is for a Sterility Assay, Line Item 119 and has a firm fixed price of USD 36,008.23. The contract was awarded on January 18, 2013 with a completion date of June 30, 2013. The place of performance is Potomac, MD.

Bioreliance Corporation, through its Life Sciences Services division, provides endotoxin, sterility, and general safety testing services for investigational new drug applications. The company has supported HHS and NIH agencies like the National Institute of Allergy and Infectious Diseases (NIAID) with isolator sterility testing, Limulus Amebocyte Lysate (LAL) endotoxin testing, and other microbiological examination and bioburden testing services to aid the Food and Drug Administration's new drug approval processes. This contract does not have a set-aside designation.

Bioreliance Corporation's parent company is Sigma-Aldrich Corporation, a leading supplier of laboratory chemicals, reagents, and other consumables. Sigma-Aldrich has primarily served as a subcontractor, providing open supply purchase orders for chemical products to support federal contracts awarded to prime contractors like Selux Diagnostics, Inc.

Quick answers

Who was awarded contract HHSN26100029?

HHSN26100029 was awarded to Bioreliance Corporation by National Cancer Institute (National Institutes of Health) on January 18, 2013.

How much is contract HHSN26100029 worth?

The government has obligated $36,008 on HHSN26100029.

Is contract HHSN26100029 an order under another contract?

Yes. HHSN26100029 is a delivery order under HHSN261200900022I, an indefinite delivery contract.

Was contract HHSN26100029 competed?

The extent of competition for HHSN26100029 was competed under sap. The government received 3 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award